









市场行情
/
股票
/
nasdaq-cmps
/

Compass Pathways PLC

CMPS

6.680USD

-0.165-2.41%

收盘 12/26, 16:00（美东）报价延迟15分钟

641.29M总市值

亏损市盈率 TTM



Compass Pathways PLC

6.680

-0.165-2.41%

概览公司财务分析

概览

公司

财务

分析

关于 Compass Pathways PLC 公司

Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.

Compass Pathways PLC简介



公司代码CMPS

公司名称Compass Pathways PLC

上市日期Sep 18, 2020

CEONath (Kabir)

员工数量166

证券类型Depository Receipt

年结日Sep 18

公司地址3Rd Floor, 1 Ashley Road

城市ALTRINCHAM

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United Kingdom

邮编WA14 2DT

电话17166766461

网址https://compasspathways.com/

公司代码CMPS

上市日期Sep 18, 2020

CEONath (Kabir)

Compass Pathways PLC公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Robert McQuade, Ph.D.

Independent Director

1.59M

Mr. Thomas Lonngren

Independent Director

89.05K

Mr. Kabir Nath

Chief Executive Officer, Executive Director

29.07K

+944.11%

Mr. David Norton

Independent Director

20.36K

+17.06%

Dr. Annalisa M. Jenkins

Independent Director

19.48K

+17.97%

Ms. Teri Loxam

Chief Financial Officer

11.21K

-86.53%

Dr. Guy Goodwin

Chief Medical Officer

1.99K

Mr. Justin Gover

Director

Ms. Daphne Karydas

Independent Director

Dr. Wayne Joseph Riley, M.D.

Independent Director

名称

名称/职务

职务

持股

持股变动

Dr. Robert McQuade, Ph.D.

Independent Director

1.59M

Mr. Thomas Lonngren

Independent Director

89.05K

Mr. Kabir Nath

Chief Executive Officer, Executive Director

29.07K

+944.11%

Mr. David Norton

Independent Director

20.36K

+17.06%

Dr. Annalisa M. Jenkins

Independent Director

19.48K

+17.97%

Ms. Teri Loxam

Chief Financial Officer

11.21K

-86.53%

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 12月15日周一

持股股东

股东类型

持股股东

占比

RTW Investments L.P.

9.07%

Deep Track Capital LP

8.19%

Atai Life Sciences AG

6.03%

GMT Capital Corp.

2.96%

Millennium Management LLC

2.83%

其他

70.93%

持股股东

占比

RTW Investments L.P.

9.07%

Deep Track Capital LP

8.19%

Atai Life Sciences AG

6.03%

GMT Capital Corp.

2.96%

Millennium Management LLC

2.83%

其他

70.93%

股东类型

持股股东

占比

Hedge Fund

27.73%

Investment Advisor/Hedge Fund

15.31%

Investment Advisor

11.88%

Individual Investor

6.10%

Corporation

6.03%

Research Firm

4.24%

Bank and Trust

1.63%

Venture Capital

0.68%

Endowment Fund

0.22%

其他

26.18%

机构持股



更新时间: 12月8日周一

报告期

机构数

持股数

持股占比

持股变动

2025Q4

283

57.38M

72.50%

+6.72K

2025Q3

301

57.46M

74.76%

+3.34M

2025Q2

285

53.63M

67.49%

+1.03M

2025Q1

275

52.65M

51.90%

+4.46M

2024Q4

270

31.64M

55.25%

-1.83M

2024Q3

260

33.66M

49.30%

+4.32M

2024Q2

262

29.34M

47.25%

+403.49K

2024Q1

263

28.00M

40.12%

+578.36K

2023Q4

271

23.51M

40.32%

+723.33K

2023Q3

272

22.78M

29.97%

+8.57M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

RTW Investments L.P.

8.22M

8.57%

+2.68M

+48.46%

Jun 30, 2025

Deep Track Capital LP

8.83M

9.2%

-28.64K

-0.32%

Jun 30, 2025

Atai Life Sciences AG

6.91M

7.2%

Mar 05, 2025

GMT Capital Corp.

1.78M

1.86%

Jun 30, 2025

Millennium Management LLC

1.74M

1.82%

-1.03M

-37.20%

Jun 30, 2025

Tang Capital Management, LLC

1.30M

1.35%

-100.00K

-7.14%

Jun 30, 2025

ARK Investment Management LLC

1.65M

1.72%

-155.58K

-8.62%

Jun 30, 2025

Goldsmith (George Jay)

2.05M

2.14%

-129.33K

-5.93%

Mar 31, 2025

Malievskaia (Ekaterina)

2.03M

2.11%

-149.38K

-6.86%

Mar 31, 2025

UBS Financial Services, Inc.

1.40M

1.46%

+402.30K

+40.20%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

AdvisorShares Psychedelics ETF

8.41%

Simplify Propel Opportunities ETF

2.71%

ARK Genomic Revolution ETF

1.23%

Virtus LifeSci Biotech Clinical Trials ETF

0.95%

ALPS Medical Breakthroughs ETF

0.24%

ProShares Ultra Nasdaq Biotechnology

0.06%

Invesco Nasdaq Biotechnology ETF

0.06%

SPDR S&P International Small Cap ETF

0.06%

iShares Biotechnology ETF

0.04%

Putnam Sustainable Future ETF

AdvisorShares Psychedelics ETF

占比8.41%

Simplify Propel Opportunities ETF

占比2.71%

ARK Genomic Revolution ETF

占比1.23%

Virtus LifeSci Biotech Clinical Trials ETF

占比0.95%

ALPS Medical Breakthroughs ETF

占比0.24%

ProShares Ultra Nasdaq Biotechnology

占比0.06%

Invesco Nasdaq Biotechnology ETF

占比0.06%

SPDR S&P International Small Cap ETF

占比0.06%

iShares Biotechnology ETF

占比0.04%

Putnam Sustainable Future ETF

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Compass Pathways PLC的前五大股东是谁？



Compass Pathways PLC 的前五大股东如下：
RTW Investments L.P.持有股份：8.22M，占总股份比例：8.57%。
Deep Track Capital LP持有股份：8.83M，占总股份比例：9.20%。
Atai Life Sciences AG持有股份：6.91M，占总股份比例：7.20%。
GMT Capital Corp.持有股份：1.78M，占总股份比例：1.86%。
Millennium Management LLC持有股份：1.74M，占总股份比例：1.82%。